Apollomics share price logo

Apollomics

NASDAQ: APLM

$26.94

-0.15

(-0.55%)

as on

Apollomics Stock Performance

as on September 2, 2026 at 2:16 pm IST

  • Day's Low

    Day's High

    $26.04
    $26.96
    downward going graph

    3.34%

    Downside

    0.07%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $3.94
    $42.12
    downward going graph

    85.37%

    Downside

    56.35%

    Upside

    downward going graph

Apollomics share price movements today

Previous Close
$27.09
Open
$26.65
Volume
82.2K
Market Cap
$78.0M
Day's Low - High
$26.04 - $26.96
52 Week Low - High
$3.94 - $42.12

Apollomics Historical Returns

1 Month Return
+ 56.22 %
3 Month Return
+ 89.72 %
1 Year Return
+ 539.9 %
3 Year Return
-94.08 %
5 Year Return
0 %

Apollomics Stock Fundamentals & Key Indicators

Check Apollomics market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$78.0M

EPS (TTM)

3.8

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

-3.56

Industry PE ratio

-3.8331543624161073

PEG Ratio

-0.02273646216080121

EBITDA

3.0M

Revenue (TTM)

-

Profit Margin

100.00%

Return On Equity TTM

288.40%

Apollomics Stock Valuation

Track how Apollomics P/E has moved over time to understand its valuation trends.

Apollomics in the last 5 years

  • Overview

  • Trends

Lowest (-9.09x)

December 31, 2021

Industry (-3.83x)

December 31, 2025

Today (-2.47x)

December 31, 2025

Highest (-0.17x)

December 31, 2024

LowHigh

Today’s Price to Earnings Ratio: -2.47x

Apollomics vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Apollomics with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
Apollomics image
Apollomics
BUY$78.0MNA-3.56100.00%NA
Revolution Medicines image
Revolution Medicines
BUY$44.6B614.61%NA0.00%NA
Vertex Pharmaceuticals image
Vertex Pharmaceuticals
BUY$137.9B174.9%31.9286.04%NA
Moderna image
Moderna
BUY$61.6B-61.21%-7.98-12.57%NA
Regeneron image
Regeneron
BUY$82.3B21.91%19.984.86%0.44%

Stock Returns calculator for Apollomics Stock including INR - Dollar returns

The Apollomics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

Apollomics investment value today

Current value as on today

₹6,90,531

Returns

₹5,90,531

(+590.53%)

Returns from Apollomics Stock

₹5,39,905 (+539.9%)

Dollar Impact

₹50,626 (+50.63%)

Analyst Recommendation on Apollomics Stock

Based on 8 analysts

BUY

87.50%

Buy

12.50%

Hold

0.00%

Sell

Based on 8 analysts, 87.5% of analysts recommend a 'BUY' rating for Apollomics. Average target price of $2

Apollomics Share Price Target

Get share price movements and forecasts by analysts on Apollomics.

What analysts predicted

-1247%DOWNSIDE

Target Price

$2

Current Price

$26.94

Analyzed by

8 Analysts

Target

$2.00

Apollomics target price $2, a slight downside of -1247% compared to current price of $26.94. According to 8 analysts rating.

Indian Investors' Interest in Apollomics Stock

Search interest for Apollomics Stock has decreased by -62% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-62% versus previous 30 day period

Apollomics Quarterly Profit & Loss

All numbers in Millions USD

Mar 2021
Jun 2021
Dec 2021
Jun 2022
Dec 2022
Jun 2023
Dec 2023
Jun 2024
Dec 2024
Dec 2025
Total Revenue
0
0
0
0
0
0
0
1
-1
-
Gross Profit
0
0
0
0
0
0
0
1
-1
-
Operating Income
-12
-25
-25
-22
-22
-25
-28
-25
-16
1
EBITDA
-12
-25
-24
-22
-21
-25
-27
-25
-15
3
Interest Expense
-
-
-
-
-
-
-
-
-
0
Depreciation
0
0
0
0
0
0
0
0
0
-
Income Before Tax
-33
-66
-28
-3
-237
-150
-21
-35
-18
1
Income Tax Expense
-
-
0
0
-
0
-
-
0
0
Net Income
-33
-66
-28
-3
-237
-150
-21
-35
-18
1
Net Profit Margin
100.00%
100.00%
100.00%
100.00%
100.00%
100.00%
100.00%
100.00%
100.00%
0.00%

Apollomics Annual Profit & Loss

All numbers in Millions USD

Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
-
1
0
0
0
0
8
Gross Profit
0
1
0
0
0
0
8
Operating Income
-24
-40
-50
-45
-54
-42
-9
EBITDA
-45
-40
-50
-43
-53
-41
-9
Interest Expense
0
0
0
0
0
0
0
Depreciation
0
0
0
0
0
0
0
Income Before Tax
-45
-74
-94
-240
-172
-53
-10
Income Tax Expense
0
0
0
0
0
0
0
Net Income
-45
-74
-94
-240
-172
-53
-10
Net Profit Margin
0.00%
100.00%
100.00%
100.00%
100.00%
100.00%
97.00%

Apollomics Quarterly Cash Flow

All numbers in Millions USD

Mar 2021
Jun 2021
Dec 2021
Jun 2022
Dec 2022
Jun 2023
Dec 2023
Jun 2024
Dec 2024
Dec 2025
Net Income
-33
-66
-28
-3
-237
-150
-21
-35
-18
-10
Operating Cash Flow
-11
-23
-19
-19
-23
-24
-18
-15
-12
-10
Investing Cash Flow
-23
-46
7
23
5
0
21
5
0
0
Financing Cash Flow
0
0
0
0
0
17
3
4
-3
3
Change in Cash
-
-
-59
-
-50
-
-
-
-
-6

Apollomics Annual Cash Flow

All numbers in Millions USD

Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-45
-74
-94
-240
-172
-53
-10
Operating Cash Flow
-21
-35
-43
-42
-43
-28
-10
Investing Cash Flow
-29
2
-38
29
21
5
0
Financing Cash Flow
9
125
-1
0
21
0
3
Change in Cash
-42
92
-83
-14
0
-22
-6

Mutual Funds that own Apollomics Stock

Check out the Mutual Funds with significant holdings in Apollomics.

Funds
Holdings
Shares Held
Fidelity Concord Street Trust
0.032558%
715

Global Institutional Holdings in Apollomics

Funds
Holdings
UBS Group AG
0.01%
SBI Securities Co Ltd
0%
HARBOUR INVESTMENTS, INC.
0%
BlackRock Inc
0%
Kestra Advisory Services, LLC
0%
See all

Insights on Apollomics

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Revenue is up for the last 3 quarters, -1.57M → 8.5M (in $), with an average increase of 104.6% per quarter

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 1 year, APLM stock has moved up by 539.9%

  • imgPOSITIVE IMPACT

    Profit Spike

    img

    Netprofit is up for the last 2 quarters, -12.53M → 1.59M (in $), with an average increase of 885.0% per quarter

  • imgPOSITIVE IMPACT

    Best in 1 Year

    img

    In the last 1 year, APLM has outperformed top 5 stocks with highest market-cap in its industry

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Revolution Medicines, Inc. Common Stock has given 37.1% return, outperforming this stock by 131.2%

About Apollomics

Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer. The company's products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer and other solid tumors with MET dysregulation; and APL-102, an oral active, small molecule multiple tyrosine kinase inhibitor, which is in a in a Phase 1 clinical trial for cancer treatment. It also develops immuno-oncology products, such as APL-501, an anti-PD-1 antibody product candidate, which is in phase 1 clinical trial for the treatment of advanced or relapsed/refractory solid tumors; APL-502, an anti-PD-L1 antibody product candidate for the treatment of tumors; APL-810, a novel, rationally designed, ACCI recombinant vaccine for the treatment of gastrin immunogen; and APL-801, a CD40 and PD-L1 antibody product candidate for the treatment of tumors. The company was founded in 2015 and is based in Foster City, California.
OrganisationApollomics
Headquarters989 East Hillsdale Blvd., Foster City, CA, United States, 94404
IndustryBiotechnology
CEOMr. Hung-Wen Chen
E-voting on sharesClick here to vote

Key Management of Apollomics

Name

Title

Mr. Hung-Wen Chen

CEO & Chairman of the Board

Mr. K. H. Lin C.A.I.A., M.B.A.

Chief Financial Officer

Mr. Yi-Kuei Chen

Director & COO

FAQs

What is Apollomics share price today?

Apollomics share price today is $26.94 as on at the close of the market. Apollomics share today touched a day high of $26.96 and a low of $26.04.

What is the 52 week high and 52 week low for Apollomics share?

Apollomics share touched a 52 week high of $42.12 on and a 52 week low of $3.94 on . Apollomics stock price today i.e. is closed at $26.94,which is 36.04% down from its 52 week high and 583.76% up from its 52 week low.

What is Apollomics's market capitalisation today?

Apollomics market capitalisation is $0.00T as on .

How to invest in Apollomics Stock (APLM) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Apollomics on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Apollomics Shares that will get you 0.0557 shares as per Apollomics share price of $26.94 per share as on September 2, 2026 at 8:46 am IST.

What is the minimum amount required to buy Apollomics Stock (APLM) from India?

Indian investors can start investing in Apollomics (APLM) shares with as little as ₹94.96 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹949.60 in Apollomics stock (as per the Rupee-Dollar exchange rate as on ). Based on Apollomics share’s latest price of $26.94 as on September 2, 2026 at 8:46 am IST, you will get 0.3712 shares of Apollomics. Learn more about fractional shares .